A clinical study investigating IFN-λ as a treatment for chronic hepatitis C indicated that, unlike IFN-α and IFN-β, IFN-λ might decrease tumor burden while increasing tumor response without any significant myelosuppression [38,39,40]. This evidence concerns the gene IFNB1 and neoplasm.